Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2015-07-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of TLC388 (Lipotecan) as a
second line treatment in subjects with advanced Hepatocellular Carcinoma.